Running Head: POLICY & COVID 19 1
Change in Policy or Practice Related to COVID 19
Student Name:
Course Name:
Name of Institute:
Word Count: 2600
, POLICY & COVID 19 2
Introduction
COVID 19 has disproportionally effected the population. Some individuals have suffered
more from others. Some suffered from symptoms only and recovered but for others it was lethal.
Healthcare sector is making efforts to understand the virulence factors of COVID 19. Some
scholars have suggested that the reason behind the disproportional transmission of COVID 19 is
related to unknown virulence aspects of virus and others have suggested the transmission and
progression of COVID infection is based on the immune system response of person. The purpose
of this paper is to discuss the reasons behind the disproportional transmission of COVID 19
infection. The paper will also formulate a plan related to healthcare research practices through
which the progression and transmission of COVID 19 infections can be reduced.
Changes in Policy or Practice Related to COVID 19
Reasons behind Disproportional Transmission of COVID 19
It is observed that COVID 19 has effected some people more adversely than others.
Those individuals who were suffering from comorbidities (for example cardiovascular
complications and cancers) suffered more from those who possess stabilized healthcare status.
Similarly, older aged group of population suffered more from young individuals. The reasons of
this disproportional transmission is linked with the reactive response of immune system. The
host immune system of some individuals have overreacted when they got exposed to COVID 19.
This over reaction of immune system became the cause of death for some individuals. The
binding of the virus depends on the ACE 2 (Angiotensin Converting Enzyme- 2) receptors.
These receptors are located on the ciliated epithelial cells of upper and lower respiratory tract.
The virus gets bind with these receptors and then invade deeply in the lungs. When they starts to
damage the lungs, then the immune system gets activated. However, patients with comorbidities
Change in Policy or Practice Related to COVID 19
Student Name:
Course Name:
Name of Institute:
Word Count: 2600
, POLICY & COVID 19 2
Introduction
COVID 19 has disproportionally effected the population. Some individuals have suffered
more from others. Some suffered from symptoms only and recovered but for others it was lethal.
Healthcare sector is making efforts to understand the virulence factors of COVID 19. Some
scholars have suggested that the reason behind the disproportional transmission of COVID 19 is
related to unknown virulence aspects of virus and others have suggested the transmission and
progression of COVID infection is based on the immune system response of person. The purpose
of this paper is to discuss the reasons behind the disproportional transmission of COVID 19
infection. The paper will also formulate a plan related to healthcare research practices through
which the progression and transmission of COVID 19 infections can be reduced.
Changes in Policy or Practice Related to COVID 19
Reasons behind Disproportional Transmission of COVID 19
It is observed that COVID 19 has effected some people more adversely than others.
Those individuals who were suffering from comorbidities (for example cardiovascular
complications and cancers) suffered more from those who possess stabilized healthcare status.
Similarly, older aged group of population suffered more from young individuals. The reasons of
this disproportional transmission is linked with the reactive response of immune system. The
host immune system of some individuals have overreacted when they got exposed to COVID 19.
This over reaction of immune system became the cause of death for some individuals. The
binding of the virus depends on the ACE 2 (Angiotensin Converting Enzyme- 2) receptors.
These receptors are located on the ciliated epithelial cells of upper and lower respiratory tract.
The virus gets bind with these receptors and then invade deeply in the lungs. When they starts to
damage the lungs, then the immune system gets activated. However, patients with comorbidities
